Indian pharmaceutical powerhouse Sun Pharmaceutical Industries Ltd. has announced its definitive agreement to acquire US-based Organon & Co. in an all-cash transaction valued at an enterprise value of $11.75 billion. This landmark deal, marking the largest overseas acquisition by an Indian pharmaceutical company, has significantly impacted both companies' stock performance.
Strategic Expansion and Market Reaction
Following the announcement, Sun Pharma's shares saw an impressive gain of 8% over two days. Concurrently, Organon & Co., listed on the NYSE, experienced a substantial surge, with its stock zooming 42% in five sessions to reach $13.16 per share. This positive market response underscores investor confidence in the strategic merits of the acquisition.
Organon & Co. specializes in key therapeutic areas, including reproductive medicine, contraception, psychiatry, hormone replacement therapy, and anesthesia. The company was spun off from MSD (Merck Sharp & Dohme) in 2021 and boasts a robust global presence, operating in over 140 markets, with strong footholds in the US, Europe, China, Canada, and Brazil. It is supported by six manufacturing facilities worldwide.
Details of the Acquisition
Under the terms of the agreement, Organon shareholders are set to receive $14 per share in cash. The acquisition aligns with Sun Pharma’s long-term strategy to expand its innovative medicines business and strengthen its presence in established brands and branded generics. Dilip Shanghvi, Executive Chairman of Sun Pharma, commented on the transaction, stating it provides an opportunity to build a more diversified platform. “Organon’s portfolio, capabilities and global reach are highly complementary to our own,” he remarked, anticipating that the combined entity would drive sustainable long-term growth.
Financial Outlook and Closing Timeline
The combined entity is projected to achieve revenues of $12.4 billion, based on FY25 estimates for Sun Pharma and CY2025 for Organon. For the year ended December 2025, Organon reported a revenue of $6.2 billion and an adjusted EBITDA of $1.9 billion, with existing debt of $8.6 billion and cash balances of $574 million.
The transaction is currently subject to various regulatory approvals and shareholder consent, with an expected closing in early 2027. This acquisition is poised to significantly reshape the global pharmaceutical landscape, enhancing Sun Pharma's global reach and therapeutic offerings.